Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AAH, ABSSI, ABSSSI, acetylsalicylic, Agila, ailment, Amblyomma, americanum, Anaplastic, Anchorage, angina, ApS, aqua, atypical, autonomy, bacteremia, Baxter, Bayer, bearing, Belsomra, BET, bevenopran, boxed, Brabant, BRAF, Bravecto, bridge, bromodomain, cardiometabolic, chewable, CHMP, cIAI, citing, clopidogrel, coadministration, Cokesbury, Colaw, complicated, compromise, CTEPH, Cubist, cUTI, cyclase, daptomycin, Decree, diarrhea, diet, disciplined, doravirine, dosage, Dutch, educate, elbasvir, Elonva, Epidermal, espionage, evidentiary, extinguishment, femoral, fewer, fluralaner, Galloping, Galper, Gaynor, gel, grazoprevir, guanylate, HABP, healthy, Hib, Hill, Hospira, Idenix, IgE, imbalance, improper, indemnify, inferred, Inter, IPR, Keytruda, kill, Labour, leakage, Liptruzet, LOFT, lumbar, Lymphoma, Madison, malware, MCC, media, mediation, microbial, mineral, mite, mutation, NGM, nonalcoholic, nosocomial, nucleotide, numeric, numerically, OBI, OncoEthix, opposed, opted, Oss, osteoporotic, overseeing, oxazolidinone, PAH, pembrolizumab, permission, phosphate, plaque, PLD, portable, postmenopausal, prodrug, Province, proximate, PSC, QIDP, quickly, radiopaque, reintroduce, repay, rescind, riociguat, Road, robert, Saflutan, Santen, sBLA, sGC, SIMADI, Sistema, Sivextro, Society, soluble, spin, spine, stake, sterile, stop, stopped, stored, surotomycin, susceptible, Taptiqom, tedizolid, teen, tender, tendered, theft, Thierry, threat, threatening, thrombotic, tick, timolol, Timoptic, tract, transcriptase, UK, unchanged, unintentional, unresectable, unstable, urinary, USPTO, VABP, validly, Vanihep, ventilated, vericiguat, web, Welfare, XE, Xellia, young, Zerbaxa, Zioptan, Zontivity
Removed:
absorption, addressed, adenosine, affirmed, African, AIT, Alabama, analgesia, announcement, antihyperglycemic, artery, Asian, Atlantic, attack, awaiting, Baby, benign, Bergen, Billingham, BioManufacturing, Bordetella, Botswana, Brian, BRIDGETTE, Carol, Carolina, carotid, ceased, Center, certified, CID, combining, commercializing, comprising, conclusion, Connectivity, consent, coupon, Dean, decongestant, default, defect, demonstrated, discontinue, distribute, diverse, dry, Endocrine, enlargement, enrolling, esomeprazole, execution, exercisable, expertise, familial, FASB, favorably, fluoroquinolone, Fujifilm, Fze, genetic, heartburn, heller, Hetero, Higbee, hypercholesterolemia, imaging, imposition, Indiana, indoor, injunctive, intrusion, investigating, Investigative, ischemic, IVAX, JJMCP, Keenan, kellogg, Kentucky, Lenovo, lining, lipid, lowered, Lupin, Marion, Martinotti, Merced, merchandiser, Merial, Millennium, Mississippi, mistrial, mixed, obstructive, occasional, Oklahoma, omeprazole, orexin, originally, outdoor, Park, Parkinson, Perk, permanently, peter, powder, prepare, preserve, progestin, promoting, proton, proven, publicly, pump, Ranbaxy, rare, rated, reclassification, recommended, Reddy, rejected, released, releasing, relinquished, remittitur, remove, representative, restructured, retail, retried, Rodney, scheduling, Scholl, School, seasonal, setting, sharing, shutdown, Sippel, sneaker, spray, stayed, Steven, stipulation, stomach, suffer, Summit, symptomatic, syndrome, targeting, TE, Torrent, tort, TPM, Transformation, Triangle, ultrasound, underway, underwritten, unenforceable, University, unrelated, urology, widely
Filing tables
Filing exhibits
- 10-K Annual report
- 10.17 Exhibit 10.17: Psu Terms for 2013 Grants
- 10.18 Exhibit 10.18: Stock Option Terms for 2014 Qtrly & Annual N-Q Option Grants
- 10.19 Exhibit 10.19: Rsu Terms for 2014 Grants
- 10.20 Exhibit 10.20: Psu Terms for 2014 Grants
- 10.23 Exhibit 10.23: Merck & Co., Inc. U.S. Separation Benefits Plan As of 111514
- 12 Exhibit 12: Computation of Ratios of Earnings to Fixed Charges
- 21 Exhibit 21: Subsidiary List
- 23 Exhibit 23: Consent of Independent Registered Public Accounting Firm
- 24.1 Exhibit 24.1: Power of Attorney
- 24.2 Exhibit 24.2: Certification of Board Resolution
- 31.1 Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification of CEO
- 31.2 Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification of CFO
- 32.1 Exhibit 32.1: Section 1350 Certification of CEO
- 32.2 Exhibit 32.2: Section 1350 Certification of CFO
- Download Excel data file
- View Excel data file
Related press release
MRK similar filings
Filing view
External links
Exhibit 32.1
Section 1350
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 27, 2015 | /s/ Kenneth C. Frazier | |
Name: KENNETH C. FRAZIER | ||
Title: Chairman, President and Chief Executive Officer |